Rapid acceleration of diagnostics (RADX) program: tech project #7360 - highly sensitive rapid test kit for sars-COV-2 that does not require a reader
Ended Definitive Contract Awarded Last action
- Contract number
- 75N92022C00003
- Awardee
-
Avantgen Inc. UEI WLNHKNPNT2M7
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,750,864
Award facts
- Opportunity
-
- 75N92022R00001 Solicitation number
- Contract value 100% obligated
- $3,750,864.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92121, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | $0 | |
| Definitize Change Order | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Definitize Letter Contract | $2,288,027 | |
| Original award | $1,462,837 |
About this award
The National Heart, Lung, and Blood Institute awarded a $3.75 million firm fixed-price definitive contract to Avantgen Inc. on November 22, 2021, to develop a highly sensitive rapid test kit for SARS-CoV-2 that does not require a reader device under the Rapid Acceleration of Diagnostics (RADx) program. The contract, which extended through September 29, 2023, is being performed in San Diego, California. No set-aside designation was used for this award. The RADx program, a coordinated federal initiative to accelerate diagnostic technology development during the COVID-19 pandemic, sought to expand availability and accessibility of testing across the United States through partnerships with private sector innovators.
Avantgen, a San Diego-based biotechnology company specializing in advanced diagnostic technologies and monoclonal antibodies, brought significant relevant expertise to this engagement, with prior experience developing rapid diagnostic test kits for infectious diseases. The company engaged Nanocomposix, Inc., a manufacturer of engineered nanoparticles, as a primary subcontractor beginning December 17, 2021, to produce materials and labor for manufacturing scale-up and pilot lot production for clinical trials. This collaboration leveraged Nanocomposix's established capabilities in lateral flow assay devices and gold nanoparticle technology previously developed for biomedical diagnostic applications through federal funding from the National Institutes of Health and other agencies.
Quick answers
Who was awarded contract 75N92022C00003?
75N92022C00003 was awarded to Avantgen Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on November 22, 2021.
How much is contract 75N92022C00003 worth?
The government has obligated $3,750,864 on 75N92022C00003.
Was contract 75N92022C00003 competed?
The extent of competition for 75N92022C00003 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award